Enfermedades raras, huérfanas y olvidadas - Afidro

Rare, orphan and neglected diseases 23
Referencias
Akobeng, A. K. (2005). Principles of evidence based medicine.
Archives of Disease in Childhood 90: 837-840.
Anónimo. (2009). Phase 0 trials: a platform for drug development?
Lancet, 374(9685): 176.
Barrera, L. A., Cely Galindo, G. (2010). Ethical aspects on
rare diseases. Advances in Experimental Medicine and Biology,
686:493-511.
Beyrer, C., Villar, J. C., Suwanvanichkij, V., Singh, S., Baral, S.
D. & Mills, E. J. (2007). Neglected diseases, civil conflicts, and
the right to health. Lancet, 370(9587):619-627.
Boy, R. & Schramm, R. F. (2009). Bioética da proteção e tratamento
de doenças genéticas raras no Brasil: o caso das doenças
de depósito lisossomal. Caderno de Saúde Pública do Rio de Janeiro,
25(6):1276-1284.
Cleemput, I., Neyt, M., Thiry, N., De Laet, C. & Leys, M. (2008).
Threshold values for cost-effectiveness in health care. Brussels:
Belgian Health Care Knowledge Centre. HTA reports. Obtenido
en octubre 26 de 2011. http://kce.fgov.be/?ID=1405
Cleemput, I., Neyt, M., Thiry, N., De Laet, C. & Leys, M. (2011).
Using threshold values for cost per quality-adjusted life-year
gained in healthcare decisions. International Journal of Technology
Assessment in Health Care, 27(1): 71-76.
Cookson, R., McCabe, C. & Tsuchiya, A. (2008). Public healthcare
resource allocation and the Rule of Rescue. Journal of Medical
Ethics, 34(7): 540-544.
Direcção-Geral da Saúde, Portugal. (2008). Programa Nacional
para Doenças Raras (PNDR). Obtenida en agosto 12 de 2011.
http://www.min-saude.pt/NR/rdonlyres/555DD3B3-45F0-4F74-
B633-28889E721BF1/0/i010420.pdf
Eurodis (2005) Rare Diseases: understanding this public
health priority. Obtenida en 3 de octubre de 2011. http://www.
orpha.net/consor/cgi-bin/Education.php?lng=ES
European Parliament and the Council of the European
Union. (2000). Regulation (EC) No. 141/2000 of the European
Parliament and of the Council of 16 December 1999 on orphan
medicinal products. Official J. Eur. Communities L18/1 – L18/5
Futerman, A. H. & van Meer, G. (2004). The cell biology of
lysosomal storage disorders. Nature Reviews Molecular Cell Biology,
5(7):554–565.
Gad, S. C. (2009). Clinical Trials Handbook. London: John
Wiley & Sons.
González de Dios, J., Sempere, A. P. & Aleixandre-Benavent,
R. (2007) Las publicaciones biomédicas en España a debate
(I): estado de las revistas neurológicas. Revista de Neurología,
44(1):32-42.
Harmatz, P., Giugliani, R., Schwartz, I., et al. (2006). Enzyme
replacement therapy for mucopolysaccharidosis VI: a phase 3,
randomized, double-blind, placebo-controlled, multinational
study of recombinant human N-acetylgalactosamine 4-sulfatase
(recombinant human arylsulfatase B or rhASB) and follow-on,
open-label extension study. Journal of Pediatrics, 148:533-539.
Kaback, M., Lim-Steele, J., Dabholkar, D., Brown, D., Levy, N.
& Zeiger, K. (1993). Tay-Sachs disease--carrier screening, prenatal
diagnosis, and the molecular era. An international perspective,
1970 to 1993. JAMA, 270(19):2307-2315.
Luisetti, M., Campo, I., Scabini, R., Zorzetto, M., Kadija, Z.,
Mariani, F. & Ferrarotti, I. (2010). The problems of clinical trials
and registries in rare diseases. Respiratory Medicine, 104
Suppl1: S42-44.
Meinert, C., & Tonascia, S. (1986). Clinical trials: design, conduct,
and analysis. New York: Oxford University Press.
Miyamoto, B. E. & Kakkis, E. D. (2011). The potential investment
impact of improved access to accelerated approval on the
development of treatments for low prevalence rare diseases. Orphanet
Journal of Rare Diseases. 6:49.
Moore, D. F., Forget, E. L., Ries, M. & Schiffmann, R. (2007)
Enzyme replacement therapy in orphan and ultra-orphan diseases:
the limitations of standard economic metrics as exemplified
by Fabry-Anderson disease. Pharmacoeconomics. 25(3):201-
208.
Muñoz, R. & Bangdiwala, S.I. (2000). Análisis interino en
ensayos clínicos: una guía metodológica. Revista Médica
de Chile 128(8): 935-941. Obtenida en octubre 8 de 2011.
Disponible en: http://www.scielo.cl/scielo.php?script=sci_
arttext&pid=S0034-98872000000800014&lng=es. doi:
10.4067/S0034-98872000000800014.